Related Experiment Video
Updated: Jul 14, 2026
A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with
Igor Bogdan Mrdovic1, Lidija Zlatimir Savic, Jovan Petar Perunicic
1Institute for Cardiovascular Diseases, Emergency Hospital, Clinical Centre of Serbia, Belgrade, Serbia. igormr@beocity.net
Insights
Carvedilol and metoprolol showed similar outcomes for major adverse events after acute myocardial infarction (AMI). However, carvedilol improved long-term quality of life and demonstrated early safety benefits in patients with left ventricular (LV) dysfunction.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Carvedilol is known to benefit patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction.
- Metoprolol's effects in this specific high-risk population have not been extensively studied.
- This study addresses the comparative efficacy of carvedilol and metoprolol post-AMI.
Purpose of the Study:
- To compare the effects of carvedilol versus metoprolol in patients experiencing LV dysfunction following AMI.
- To evaluate differences in composite adverse events, hard cardiac events, and health-related quality of life.
Main Methods:
- 313 high-risk patients with anterior AMI and LV ejection fraction <45% were randomized.
- Patients received either carvedilol or metoprolol and were followed for a mean of 13.4 months.
- Primary endpoint: time to composite adverse events (t-CAE); Secondary endpoints: time to composite hard events (t-CHE) and quality of life.
Main Results:
- No significant differences were observed between carvedilol and metoprolol for t-CAE or t-CHE.
- Carvedilol treatment led to significant improvements in 4 out of 8 health-related quality of life domains.
- Fewer patients in the carvedilol group were withdrawn from therapy during hospitalization.
Conclusions:
- Carvedilol and metoprolol offer comparable efficacy regarding major adverse and hard cardiac events in AMI patients with LV dysfunction.
- Carvedilol provides superior long-term quality of life benefits.
- Carvedilol exhibits a favorable early safety profile compared to metoprolol in this patient cohort.
Background:
Carvedilol has previously been demonstrated to be beneficial in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction. However, metoprolol has not to date been randomly evaluated in the same patient population. The objective of this study was to compare the effects of treatment with carvedilol versus metoprolol in patients with LV dysfunction after AMI.
Methods:
The study enrolled 313 high-risk patients with anterior AMI and LV ejection fraction of <45%, randomly assigned to treatment with carvedilol or metoprolol. Patients were followed-up for a mean period of 13.4 months. The primary end point was time to composite adverse events (t-CAE). The secondary end points were time to composite hard events (t-CHE) and health-related quality of life.
Results:
No differences were found either in the primary end point of t-CAE or in the secondary end point of t-CHE. A significant benefit was observed in 4 of 8 health-related quality of life domains in the carvedilol group, with fewer carvedilol group patients being withdrawn from therapy in the hospital.
Conclusions:
Treatment with carvedilol, in comparison to that with metoprolol in patients with AMI and LV dysfunction, did not differ significantly in regard to the primary end point of t-CAE or to the secondary end point of t-CHE but resulted in better long-term quality of life and favorable early safety profile.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:29Cardiomyopathy V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers